TN80 Stock Overview
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.60 |
| 52 Week High | US$15.60 |
| 52 Week Low | US$13.10 |
| Beta | 0.79 |
| 11 Month Change | -3.55% |
| 3 Month Change | -6.21% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| TN80 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -3.8% | -0.6% |
| 1Y | n/a | -16.2% | 2.9% |
Return vs Industry: Insufficient data to determine how TN80 performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how TN80 performed against the German Market.
Price Volatility
| TN80 volatility | |
|---|---|
| TN80 Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: TN80 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TN80's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 122,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TN80 fundamental statistics | |
|---|---|
| Market cap | €199.17b |
| Earnings (TTM) | €5.65b |
| Revenue (TTM) | €39.79b |
35.2x
P/E Ratio5.0x
P/S RatioIs TN80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TN80 income statement (TTM) | |
|---|---|
| Revenue | US$42.49b |
| Cost of Revenue | US$25.34b |
| Gross Profit | US$17.15b |
| Other Expenses | US$11.12b |
| Earnings | US$6.03b |
Last Reported Earnings
Mar 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.81 |
| Gross Margin | 40.37% |
| Net Profit Margin | 14.20% |
| Debt/Equity Ratio | 77.7% |
How did TN80 perform over the long term?
See historical performance and comparison